Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E54.88 EPS (ttm)1.20 Insider Own0.10% Shs Outstand1.67B Perf Week2.99%
Market Cap109.77B Forward P/E28.50 EPS next Y2.31 Insider Trans-24.24% Shs Float1.66B Perf Month-3.04%
Income2.00B PEG3.40 EPS next Q0.50 Inst Own72.60% Short Float1.31% Perf Quarter6.31%
Sales15.88B P/S6.91 EPS this Y-22.10% Inst Trans-0.02% Short Ratio3.49 Perf Half Y35.42%
Book/sh8.95 P/B7.36 EPS next Y34.52% ROA6.00% Target Price65.90 Perf Year36.73%
Cash/sh4.46 P/C14.76 EPS next 5Y16.15% ROE13.20% 52W Range45.09 - 68.80 Perf YTD12.21%
Dividend1.48 P/FCF490.03 EPS past 5Y-5.90% ROI6.40% 52W High-4.28% Beta0.25
Dividend %2.25% Quick Ratio1.50 Sales past 5Y-3.30% Gross Margin76.20% 52W Low46.06% ATR1.28
Employees25000 Current Ratio1.70 Sales Q/Q-4.10% Oper. Margin22.20% RSI (14)61.71 Volatility1.75% 1.88%
OptionableYes Debt/Eq0.53 EPS Q/Q-97.70% Profit Margin12.60% Rel Volume1.50 Prev Close65.86
ShortableYes LT Debt/Eq0.49 EarningsApr 28 BMO Payout119.80% Avg Volume6.26M Price65.86
Recom2.30 SMA202.38% SMA503.83% SMA20017.22% Volume0 Change0.00%
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Jan-09-12Reiterated Barclays Capital Overweight $34 → $36
Oct-19-11Initiated MKM Partners Sell $26
Jun-27-11Reiterated UBS Neutral $28 → $30
Mar-31-11Downgrade Jefferies Buy → Hold $28.50
Mar-28-11Reiterated Barclays Capital Overweight $28 → $30
Sep-22-10Reiterated Deutsche Bank Buy $28 → $31.50
Sep-01-10Reiterated UBS Neutral $26 → $27
Apr-21-15 08:55AM  Top Analyst Upgrades and Downgrades: GE, IBM, Bristol-Myers, Encana, Halliburton, Rio Tinto, WhiteWave and More at 24/7 Wall St.
12:13AM  Bristol-Myers Drug Combination Shows Promise Against Melanoma at The Wall Street Journal
Apr-20-15 07:11PM  Final Glance: Pharmaceuticals companies
06:26PM  Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog
05:58PM  Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog
05:31PM  Bristol, Merck Cancer Drugs Strut Their Stuff at Investor's Business Daily
05:17PM  New data boosts biotechs
04:04PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K/A, Change in Directors or Principal Officers
01:55PM  Bristol-Myers combination melanoma treatment shows promise at Financial Times
01:21PM  Bristol-Myers: 2 cancer drugs beat 1 against melanoma
01:17PM  Midday Glance: Pharmaceuticals companies
10:38AM  Early Glance: Pharmaceuticals companies
09:48AM  Test May Show Merck Melanoma Drugs Success in Lung Cancer at Bloomberg
09:10AM  3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings at 24/7 Wall St.
09:01AM  Immune System Drugs Melt Tumors In New Study, Leading A Cancer Revolution at Forbes
08:47AM  First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma at noodls
08:30AM  Bristol-Myers Drug Combination Shows Promise at The Wall Street Journal
08:30AM  First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma Business Wire
12:16AM  Mercks Keytruda Shows Improved Survival Odds in Melanoma at The Wall Street Journal
Apr-19-15 05:20PM  Merck Drug Shows Improved Odds for Melanoma Patients at The Wall Street Journal
02:56PM  Studies: Merck drug Keytruda effective against 3 cancers
12:26PM  Merck's Keytruda shrinks lung cancer tumors, FDA approval sought
08:00AM  Merck files for FDA approval of Keytruda in lung cancer Reuters
Apr-17-15 11:53PM  Overheard: Bristol-Myers Zigs While Market Zags at The Wall Street Journal
04:45PM  Bristol-Myers to Transfer Certain Erbitux Rights to Eli Lilly - Analyst Blog
04:42PM  Promising cancer drugs
02:27PM  Bristol-Myers Zigs While Market Zags at The Wall Street Journal
11:23AM  With Bristol-Myers Trial Stopped Early, 'What's Next?'
10:51AM  Mattel rallies on narrower loss, Amex blames dollar for revenue drop at MarketWatch
10:44AM  Bristol's Opdivo Scores Again Against Lung Cancer at Investor's Business Daily
10:23AM  Bristol-Myers Up Big After Drug Study Stopped Early
09:48AM  Bristol-Myers stops lung cancer trial after positive results at MarketWatch
09:19AM  Bristol's Opdivo proves effective against second type of lung cancer Reuters
08:55AM  CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Business Wire
Apr-16-15 02:57PM  Bristol-Myers Deal Flags Three Gene-Therapy Picks at Barrons.com
01:27PM  Bristol-Myers to Sell Cancer Drug Rights to Eli Lilly at The Wall Street Journal
12:30PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
12:29PM  Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America at noodls
12:19PM  Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America at noodls
12:15PM  Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America Business Wire
Apr-15-15 11:13AM  Lexicon Pharmaceuticals and Bristol-Myers Squibb Select Development Candidate for Neuropathic Pain in Neuroscience Drug Discovery and Development Alliance at noodls
Apr-14-15 07:06PM  The Medicines Co.'s Kengreal Briefing Documents Positive - Analyst Blog
04:09AM  Corporate Pension Funds Pile Into Bonds at The Wall Street Journal
Apr-13-15 04:28PM  Roche aims for 11 late-stage trials in cancer immunotherapy drug this year Reuters
04:10PM  AstraZeneca's Onglyza Briefing Documents Raise Concern - Analyst Blog
Apr-11-15 12:34PM  Specialty, generic drug costs drive Medicaid costs up
Apr-10-15 04:23PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:57AM  How Bristol-Myers Squibb Makes the World Healthier at Investopedia
Apr-08-15 05:15PM  Peninsula drug company's blood-thinner antidote could reach FDA this year at bizjournals.com
11:42AM  Pfizer, Eli Lilly Were The Original Medical Marijuana Sellers at Forbes
08:25AM  Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc. at noodls
08:00AM  Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc. Business Wire
Apr-07-15 05:14PM  Celldex Initiates Study on Varlilumab for Metastatic Melanoma - Analyst Blog
11:44AM  Celldex Up As Breast-Cancer Drug Shows Promise at Investor's Business Daily
10:30AM  4 Big Pharmaceutical Stocks to Buy for the Rest of 2015 at 24/7 Wall St.
10:10AM  Company News for April 07, 2015 - Corporate Summary
08:02AM  Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched at TheStreet
07:10AM  Biotech on verge of first clinical trial scores $35 million round at bizjournals.com
12:19AM  [$$] Bristol-Myers Invests in Dutch Company uniQure at The Wall Street Journal
Apr-06-15 05:27PM  Bristol-Myers Invests in uniQure in Heart-Disease Pact at The Wall Street Journal
01:58PM  Bristol-Myers Squibb (BMY) Invests in uniQure (QURE) to Develop Gene Therapies for Heart Diseases - Stocks in the News
01:07PM  Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases at noodls
12:34PM  Bristol-Myers to invest in Dutch gene therapy company uniQure
11:58AM  UniQure soars on Bristol-Myers deal; Qualcomm slides
10:04AM  Bristol-Myers Squibb (BMY) Stock Falls Slightly on UniQure Investment, Collaboration at TheStreet
09:38AM  Bristol-Myers buys into Dutch gene therapy company uniQure
09:30AM  Bristol to Buy Stake in UniQure, Maker of First $1 Million Drug at Bloomberg
09:07AM  Stock Futures Aim Sharply Lower; UniQure Spikes, Herbalife Dives at Investor's Business Daily
08:40AM  Bristol-Myers, UniQure To Team Up On Heart Disease at Investor's Business Daily
07:51AM  uniQure Announces Webcast to Discuss Bristol-Myers Squibb Collaboration at noodls
07:40AM  Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases at noodls
07:32AM  Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases Business Wire
Apr-02-15 04:17PM  Effective Risk Control With Scaling Trading Strategies at Investopedia
12:06PM  Why Pfizers Leverage Is Important to Investors
Apr-01-15 06:34PM  Merck Inks Deal with Syndax for Cancer Combo Therapy - Analyst Blog
10:06AM  Pfizers Global Established Pharmaceutical Segment
06:00AM  Roche open to alliances in hunt for cancer drug combinations Reuters
Mar-31-15 11:57AM  Health-care hedge fund Orbimed's top picks at MarketWatch
10:17AM  Millions To Be Made On...Generic Drugs? at Forbes
Mar-30-15 10:50AM  Bristol-Myers Squibb Is Re-Testing Its Breakout Level
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases
Mar-27-15 04:01PM  Pfizer: A Leading Pharmaceutical Company
02:50PM  Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog
02:40PM  Immune Design Starts Dosing Patients in CMB305 Study - Analyst Blog
12:37PM  11 promising drugs poised to be the next billion-dollar blockbusters
11:14AM  Europe pushes back verdict on Bristol immune system cancer drug Reuters
10:40AM  Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28 at noodls
10:08AM  Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28 Business Wire
08:49AM  Europe postpones decision on Bristol immune system cancer drug Reuters
Mar-26-15 12:02PM  Healthcare Hedge Fund Orbimeds Top Picks and New Move at Insider Monkey
08:55AM  Merck in $10B Buyback; Keytruda Tops Melanoma Study - Analyst Blog
Mar-25-15 03:51PM  Good time for investors to jump in: Pro
01:14PM  Science, patients driving rare disease drug research surge
Mar-24-15 03:33PM  Merck halts study in light of melanoma drugs success at Fortune
02:58PM  Hottest dividend stocks of 2015 at CNBC
01:10PM  Two Healthcare Stocks Provide Antidotes To Wild Market Swings at Forbes
10:37AM  Merck's Keytruda Bests Yervoy In Early Melanoma at Investor's Business Daily
10:00AM  Merck says melanoma drug meets goal; study halted
09:30AM  Bristol-Myers Squibb (BMY) Stock Price Target Increased at BMO at TheStreet
08:27AM  Bristol-Myers buys rights to Novo Nordisk immune system project
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company's products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,55409,047Apr 03 03:39 PM
Cuss Francis MEVP & CSOMar 16Option Exercise25.52114,0102,909,160380,699Mar 17 05:54 PM
Cuss Francis MEVP & CSOMar 16Sale67.81114,6667,775,501266,033Mar 17 05:54 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 16Sale67.087,000469,56022,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 13Sale66.6759139,40231,015Mar 16 07:01 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 13Sale66.795,000333,97229,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.002,068042,368Mar 12 06:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.005,287035,218Mar 12 06:54 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.003,271052,348Mar 12 06:54 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.008,0190269,160Mar 12 06:54 PM
Caforio GiovanniChief Operating OfficerMar 10Option Exercise0.0010,579071,322Mar 12 06:54 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.001,788050,485Mar 12 06:55 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.005,212058,799Mar 12 06:55 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.002,977076,835Mar 12 06:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0013,2390184,290Mar 12 06:55 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0048,8500411,731Mar 12 06:56 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.009,9970307,535Mar 12 06:53 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.004,54608,057Mar 12 06:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Sale65.8410,343680,94231,606Mar 12 06:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043059,141Mar 10 04:53 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931074,668Mar 10 04:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043040,624Mar 10 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400374,863Mar 10 04:51 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528030,053Mar 10 04:52 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724048,631Mar 10 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390054,339Mar 10 04:53 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0090261,937Mar 10 04:54 PM
Caforio GiovanniChief Operating OfficerMar 06Option Exercise0.002,889061,986Mar 10 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230171,251Mar 10 04:52 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 06Option Exercise0.005,5730298,970Mar 10 04:52 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Sale66.2410,468693,45249,031Mar 10 04:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.008,250060,609Mar 04 09:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.008,249043,860Mar 04 09:38 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 02Option Exercise0.0019,995034,176Mar 04 09:38 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 02Option Exercise0.0044,0840316,255Mar 04 09:39 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.0022,851070,125Mar 04 09:37 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.0023,8030270,105Mar 04 09:37 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.0018,907060,423Mar 04 09:37 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.005,725050,278Mar 04 09:37 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.0015,271079,730Mar 04 09:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.00231,2800643,964Mar 04 09:36 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.001,033044,363Mar 04 05:14 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 02Option Exercise0.009,7470108,016Mar 04 05:14 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.003,7030245,358Mar 04 05:14 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.003,182040,705Mar 04 05:14 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.001,360051,827Mar 04 05:12 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.002,475064,025Mar 04 05:13 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.001,174035,654Mar 04 05:13 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.001,494046,893Mar 04 05:13 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.0033,5310416,594Mar 04 05:13 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Option Exercise25.4515,000381,750275,656Feb 18 05:32 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Sale60.3911,746709,282263,910Feb 18 05:32 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 12Sale59.263,880229,93334,480Feb 13 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Option Exercise22.1427,938618,54759,838Feb 10 06:11 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Sale60.1521,4781,291,98838,360Feb 10 06:11 PM
CORNELIUS JAMES MDirectorJan 30Sale60.6050,0003,029,975119,464Feb 03 06:18 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Option Exercise25.45112,5002,863,125473,309Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Option Exercise26.252,50065,6252,500Feb 02 07:05 PM
Schmukler Louis SPres., Global Mfg. & SupplyJan 29Sale60.735,250318,85014,182Feb 02 07:05 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Sale61.1490,2465,518,001383,063Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Sale60.892,500152,2270Feb 02 07:05 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00952050,808Jan 06 06:56 PM
ANDREOTTI LAMBERTOChief Executive OfficerDec 05Sale60.3175,0004,522,944360,809Dec 05 05:39 PM
ANDREOTTI LAMBERTOChief Executive OfficerNov 05Sale57.7975,0004,334,153435,809Nov 07 05:13 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660245,112Nov 04 05:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,102099,666Nov 04 05:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 24Sale53.0050,0002,650,000510,809Oct 28 04:23 PM
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM